We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+8.59%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$102M
AUM Growth
-$835K
Cap. Flow
-$2.14M
Cap. Flow %
-2.1%
Top 10 Hldgs %
58.99%
Holding
87
New
21
Increased
24
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$4.68M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.45M
3
ARDX icon
Ardelyx
ARDX
+$2.29M
4
ALMS
Alumis Inc
ALMS
+$1.65M
5
ITOS
iTeos Therapeutics
ITOS
+$1.61M

Top Sells

Rank Stock Value
1
OPTN
OptiNose
OPTN
+$7.23M
2
URGN icon
UroGen Pharma
URGN
+$3.69M
3
AQST icon
Aquestive Therapeutics
AQST
+$3.04M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.36M
5
ESTA icon
Establishment Labs
ESTA
+$2.35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INAB icon
51
IN8bio
INAB
$10.3M
$172K 0.17%
+82,430
New +$335K
NUVB icon
52
Nuvation Bio
NUVB
$2.29B
$166K 0.16%
+85,300
New +$178K
KURA icon
53
Kura Oncology
KURA
$793M
$144K 0.14%
+25,000
New +$153K
CLYM
54
Climb Bio
CLYM
$693M
$144K 0.14%
+116,147
New +$145K
CALC icon
55
CalciMedica
CALC
$11.7M
$136K 0.13%
85,000
-282,371
-77% -$485K
GLUE icon
56
Monte Rosa Therapeutics
GLUE
$1.82B
$135K 0.13%
+30,000
New +$134K
ZNTL icon
57
Zentalis Pharmaceuticals
ZNTL
$332M
$126K 0.12%
109,010
+49,010
+82% +$64.6K
BOLD
58
Boundless Bio
BOLD
$55.7M
$107K 0.11%
+106,175
New +$141K
CHRS icon
59
Coherus Oncology
CHRS
$217M
$45.9K 0.05%
62,700
-557,888
-90% -$482K
ACET icon
60
Adicet Bio
ACET
$77.6M
– –
-31,767
Closed -$204K
AMRN
61
Amarin Corp
AMRN
$297M
– –
-32,581
Closed -$105K
APRE icon
62
Aprea Therapeutics
APRE
$7.69M
– –
-102,242
Closed -$14.4K
AQST icon
63
Aquestive Therapeutics
AQST
$452M
– –
-200,000
Closed -$3.04M
CRBP icon
64
Corbus Pharmaceuticals
CRBP
$165M
– –
-35,000
Closed -$186K
CRGX
65
DELISTED
CARGO Therapeutics
CRGX
– –
-50,000
Closed -$204K
EBS icon
66
Emergent Biosolutions
EBS
$379M
– –
-5,000
Closed -$24.3K
EDSA icon
67
Edesa Biotech
EDSA
$51.6M
– –
-687,500
Closed -$1.68M
ELAN icon
68
Elanco Animal Health
ELAN
$13.2B
– –
-10,000
Closed -$105K
ESPR
69
DELISTED
Esperion Therapeutics
ESPR
– –
-10,000
Closed -$14.4K
LKFT
70
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-93,968
Closed -$2.36M
NBP
71
NovaBridge Biosciences American Depositary Shares
NBP
$186M
– –
-483,647
Closed -$398K
INO icon
72
Inovio Pharmaceuticals
INO
$85.6M
– –
-518,331
Closed -$845K
IOVA icon
73
Iovance Biotherapeutics
IOVA
$2.04B
– –
-20,000
Closed -$66.6K
KROS icon
74
Keros Therapeutics
KROS
$197M
– –
-100,000
Closed -$1.02M
MIST icon
75
Milestone Pharmaceuticals
MIST
$129M
– –
-250,000
Closed -$200K
1 2
3
4

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Stonepine Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Stonepine Capital Management held 87 positions worth $102M, down 0.81% from $103M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Stonepine Capital Management's Q2 2025 filing shows 21 new, 24 increased, 14 reduced and 28 closed positions. Its largest new stake was Ardelyx: 555,000 shares worth $2.18M. The largest sale was OptiNose, an estimated $7.23M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2025 buy was Ardelyx: 555,000 shares worth $2.18M.
  • Stonepine Capital Management added most to Verastem in Q2 2025, an estimated $4.68M increase.
  • Stonepine Capital Management's biggest Q2 2025 reduction was Establishment Labs, cutting an estimated $2.35M.
  • Stonepine Capital Management fully exited OptiNose in Q2 2025, selling an estimated $7.23M.
  • Stonepine Capital Management's ten largest holdings make up 59% of its $102M portfolio in Q2 2025.
  • Stonepine Capital Management opened 21 new positions and closed 28 in Q2 2025.
  • Stonepine Capital Management's portfolio value fell 0.81% quarter-over-quarter to $102M.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.